Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 44: 1443-1451, 1998;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (17)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nauck, M.
Right arrow Articles by Wieland, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nauck, M.
Right arrow Articles by Wieland, H.
Related Collections
Right arrow Lipids, Lipoproteins, and Cardiovascular Risk Factors
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 1998;44:1443-1451.)
© 1998 American Association for Clinical Chemistry, Inc.

Lipids and Lipoproteins

New immunoseparation-based homogeneous assay for HDL-cholesterol compared with three homogeneous and two heterogeneous methods for HDL-cholesterol

Matthias Naucka, Winfried März, and Heinrich Wieland

a Address correspondence to this author at: Department of Medicine, Division of Clinical Chemistry, Hugstetter Strasse 55, 79106 Freiburg i. Br., Germany. Fax 49-761-270 3444; e-mail manauck{at}mzl200.ukl.uni-freiburg.de.

We evaluated four new commercial methods for HDL-cholesterol determination. The three completely homogeneous assays were an immunoseparation-based (IS) method from Wako, a polyethylene glycol-modified enzyme (PEG) method from Boehringer Mannheim, and a synthetic polymer-based (SP) method from Genzyme. The fourth method was a new heterogeneous method in which lipoproteins are removed using dextran sulfate-coated magnetic beads and Mg2+ (MB, Reference Diagnostics). We compared these methods with the conventional phosphotungstic acid/MgCl2 precipitation (PTA) procedure. The homogeneous assays had good intraassay imprecision with total CVs <2.3%, whereas the CVs of the MB assay were <5.9%. Adding HDL to serum to achieve HDL-cholesterol (HDL-C) concentrations up to 1000 mg/L revealed nearly complete recoveries in the IS, PEG, and MB assays, whereas the SP assay showed a lower recovery (~70%). The SP HDL-C apparently increased at increasing LDL-cholesterol and VLDL-triglyceride concentrations, whereas the IS, PEG, and MB methods were not influenced by LDL-cholesterol up to 6 000 mg/L (MB, 5 000 mg/L) and VLDL-triglycerides up to 9 000 mg/L. Free fatty acids above ~2 mmol/L produced falsely high HDL-C in the IS and SP assays, the error amounting to as much as 50% in some samples. An intermethod comparison in 291 fresh serum samples yielded correlation coefficients of at least r = 0.95 for all assays, when compared with the PTA procedure. The slopes and intercepts of the regression lines were 1.05 and 57 (IS), 1.12 and 9.9 (PEG), 1.00 and 39 (SP), and 1.0 and 38 mg/L (MB), respectively. The new assays are precise and simplify the determination of HDL-C, but in part they lack specificity or are susceptible to interferences, resulting in discrepancies when compared with the established PTA procedure.




The following articles in journals at HighWire Press have cited this article:


Home page
 Eur Respir JHome page
J. Borgel, B. M. Sanner, A. Bittlinsky, F. Keskin, N. K. Bartels, N. Buechner, A. Huesing, L. C. Rump, and A. Mugge
Obstructive sleep apnoea and its therapy influence high-density lipoprotein cholesterol serum levels
Eur. Respir. J., January 1, 2006; 27(1): 121 - 127.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
G. R. Warnick, M. Nauck, and N. Rifai
Evolution of Methods for Measurement of HDL-Cholesterol: From Ultracentrifugation to Homogeneous Assays
Clin. Chem., September 1, 2001; 47(9): 1579 - 1596.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. L. Sampson, A. Aubry, G. Csako, and A. T. Remaley
Triple Lipid Screening Test: A Homogeneous Sequential Assay for HDL-Cholesterol, Total Cholesterol, and Triglycerides
Clin. Chem., March 1, 2001; 47(3): 532 - 539.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
A. M. Wagner, J. L. Sanchez-Quesada, A. Perez, M. Rigla, M. Cortes, F. Blanco-Vaca, and J. Ordonez-Llanos
Inaccuracy of Calculated LDL-Cholesterol in Type 2 Diabetes: Consequences for Patient Risk Classification and Therapeutic Decisions
Clin. Chem., November 1, 2000; 46(11): 1830 - 1832.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. L. Sampson, G. Csako, and A. T. Remaley
Estimation of Serum Apolipoprotein B by a Modified Homogeneous Assay for HDL-Cholesterol,
Clin. Chem., June 1, 2000; 46(6): 869 - 871.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Association for Clinical Chemistry.